Table 2 Holdings of public and quasi-public institutional investors in Roche and Alexion Pharmaceuticals - companies whose drugs were denied reimbursement by health insurers in high-income countries due to high prices
From: Pension and state funds dominating biomedical R&D investment: fiduciary duty and public health
Fund | Assets under management, USD million | Holdings in Hoffmann-La Roche Ltd. (marketer of bevacizumab), USD million | Holdings in Alexion Pharmaceuticals Inc. (marketer of eculizumab), USD million | Date |
|---|---|---|---|---|
ABP (Netherlands; pension fund for employees in the government and education sectors) | 498250 | 649 | 134 | 3/2018 |
Canadian Pension Plan Investment Board | 238160 | 689 | 41 | 3/2017 |
British Columbia Investment Management Corporation (Canada) | 101890 | 109 | 25 | 3/2017 |
New Zealand Superannuation Fund | 27670 | 43 | 6 | 6/2017 |
Strathclyde Pension Fund (UK) | 28230 | – | 6 | 12/2017 |
West Yorkshire Pension Fund (UK) | 19500 | 43 | – | 3/2017 |
Swiss National Bank (Switzerland) | 92585 (US equities only) | – | 98 | 2/2018 |
European Central Bank (EU) | 185140 | 9260 in health & life sciences corporate bonds in total, mostly Bayer, Merck (Germany), Novartis, Roche and Sanofi. Holdings per firm not disclosed. | – | 4/2018 |